Trifecta Capital Advisors LLC Raises Holdings in Boston Scientific Corporation $BSX

Trifecta Capital Advisors LLC boosted its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 6.9% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 46,411 shares of the medical equipment provider’s stock after acquiring an additional 3,010 shares during the quarter. Trifecta Capital Advisors LLC’s holdings in Boston Scientific were worth $4,985,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. GAMMA Investing LLC increased its holdings in Boston Scientific by 15.4% during the second quarter. GAMMA Investing LLC now owns 29,486 shares of the medical equipment provider’s stock valued at $3,167,000 after buying an additional 3,932 shares during the period. Bank of New Hampshire increased its holdings in Boston Scientific by 552.0% during the second quarter. Bank of New Hampshire now owns 19,724 shares of the medical equipment provider’s stock valued at $2,119,000 after buying an additional 16,699 shares during the period. MRA Advisory Group purchased a new position in Boston Scientific during the second quarter valued at approximately $273,000. NS Partners Ltd increased its holdings in Boston Scientific by 1.6% during the first quarter. NS Partners Ltd now owns 368,189 shares of the medical equipment provider’s stock valued at $37,143,000 after buying an additional 5,704 shares during the period. Finally, Neville Rodie & Shaw Inc. increased its holdings in Boston Scientific by 95.9% during the second quarter. Neville Rodie & Shaw Inc. now owns 45,460 shares of the medical equipment provider’s stock valued at $4,883,000 after buying an additional 22,255 shares during the period. 89.07% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have issued reports on BSX. Leerink Partnrs raised shares of Boston Scientific to a “strong-buy” rating in a report on Monday, June 16th. Erste Group Bank lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Friday, October 3rd. Wells Fargo & Company lifted their price target on shares of Boston Scientific from $118.00 to $124.00 and gave the stock an “overweight” rating in a report on Thursday, July 24th. Wall Street Zen lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Friday, October 3rd. Finally, UBS Group lifted their price target on shares of Boston Scientific from $130.00 to $135.00 and gave the stock a “buy” rating in a report on Thursday, July 24th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, Boston Scientific presently has a consensus rating of “Buy” and a consensus target price of $120.71.

Insider Buying and Selling at Boston Scientific

In related news, Director Edward J. Ludwig sold 4,000 shares of the business’s stock in a transaction on Friday, July 25th. The shares were sold at an average price of $106.03, for a total transaction of $424,120.00. Following the completion of the transaction, the director directly owned 18,479 shares in the company, valued at $1,959,328.37. The trade was a 17.79% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Yoshiaki Fujimori sold 2,901 shares of the business’s stock in a transaction on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total transaction of $310,377.99. Following the transaction, the director owned 2,081 shares of the company’s stock, valued at $222,646.19. This represents a 58.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 174,214 shares of company stock valued at $17,972,457. Company insiders own 0.50% of the company’s stock.

Boston Scientific Trading Up 0.9%

NYSE BSX opened at $96.73 on Thursday. The company has a market capitalization of $143.33 billion, a PE ratio of 57.58, a P/E/G ratio of 2.31 and a beta of 0.61. The company has a fifty day moving average of $102.34 and a 200 day moving average of $101.96. Boston Scientific Corporation has a 1 year low of $80.64 and a 1 year high of $109.50. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. The company had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The firm’s quarterly revenue was up 22.8% on a year-over-year basis. During the same period in the previous year, the firm posted $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Research analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.